New MRI-Ultrasound fusion aims to sharpen prostate cancer detection

NCT ID NCT05064111

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new software that combines MRI images with real-time ultrasound to guide prostate biopsies. The goal is to help doctors more accurately detect and locate aggressive prostate cancer early. About 100 men scheduled for a standard prostate biopsy will take part. The research focuses on improving diagnosis, not on treating the cancer itself.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

image fusion software

What this could lead to

If successful, this could make prostate cancer biopsies more accurate, helping doctors find aggressive cancers earlier and choose better treatments.

What could go wrong

This is an early-stage study testing a software add-on, not a new treatment. The trial is currently suspended, and the software is not yet FDA-approved, so results may not lead to immediate changes in practice.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate adenocarcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Arizona

    Tucson, Arizona, 85724, United States